522650-83-5
522650-83-5
Chemical Structure
SW044248
- CAS No.: 522650-83-5
- Formula:C22H23N5O2S
- Molecular Weight:421.52
IUPAC Name: 2-((5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)-N-(2-methoxyphenyl)butanamide
InChIKey: PEVRGVRHMMZNGI-UHFFFAOYSA-N
SMILES: CCC(SC1=NN=C2C(N(CC)C3=C2C=CC=C3)=N1)C(NC4=CC=CC=C4OC)=O
Biological Activity: SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SW044248 | 98.92% | SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OB-2 | OB-2 is a STOML3 oligomerization blocker. OB-2 reverses pathological mechanical hypersensitivity. OB-2 can be used for research of painful diabetic neuropathy in mice. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Primordazine B | Primordazine B is a small molecule compound identified by chemical screening in zebrafish embryos with the activity of selectively destroying Primordial Germ Cells (PGCs). Primordazine B inhibits a process called Poly(A)-tail Independent Non-canonical Translation (PAINT) without inhibition of polyadenylate tail dependent typical translation (PAT). Primordazine B can be used to study translational control of cells in specific physiological or pathological states, such as gene expression regulation during cell dormancy, viral infection, or stress conditions. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Primordazine NC-6364997 | Primordazine NC-6364997 (compound 3) is a negative control between Primordazine A and Primordazine B. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
dCeMM2 | 99.25% | dCeMM2 (Compound 2) is a molecular glue-type degrader that targets cyclin K. dCeMM2 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SIRT2-IN-9 | 99.45% | SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SIRT2-IN-10 | SIRT2-IN-10 (Compound 12) is a potent SIRT2 inhibitor with an IC50 of 1.3 μM. SIRT2-IN-10 can be used for the research of cancer and neurodegenerative disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inauhzin | 98.46% | Inauhzin is a dual SirT1/IMPDH2 inhibitor, and acts as an activator p53, used in the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
I3IN-002 | 99.35% | I3IN-002 is a small-molecule RNA-binding protein IGF2BP3 inhibitor with an IC50 value of approximately 2 μM in SEM cells. I3IN-002 interferes with interaction with m6 A-modified mRNAs, disrupting the stabilization of target genes (such as CDK6, MYC, and BCL2) to inhibit leukemic cell growth, induce cell cycle arrest, and promote apoptosis. I3IN-002 is promising for research of B-cell acute lymphoblastic leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IGF2BP3-IN-1 | 99.05% | IGF2BP3-IN-1 (Compound I3IN-122) is an IGF2BP3 (a RNA binding protein) inhibitor (IC50: > 50 μM), and can be used for cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SR94 | SR94, a SR17 derivative, is a SIRT2 inhibitor that contains an arbitrary 6-member ring and different R2 groups. SR94 is promising for research of cancer, ischemia-reperfusion and neurodegenerative diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
